|
| 33153882 | Targeting barriers to wider use of trimodality therapy in localized muscle invasive bladder cancer. | Urol Oncol | 2023 |
| 37596191 | Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605. | Eur Urol | 2023 |
| 37490155 | Approaches to Prevent and Manage Cardiovascular Disease in Patients Receiving Therapy for Prostate Cancer. | Curr Cardiol Rep | 2023 |
| 37192435 | Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium. | J Clin Oncol | 2023 |
| 36980557 | Performing Automatic Identification and Staging of Urothelial Carcinoma in Bladder Cancer Patients Using a Hybrid Deep-Machine Learning Approach. | Cancers (Basel) | 2023 |
| 37142291 | Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial. | J Immunother Cancer | 2023 |
| 37099429 | Workflow in transgenic mice for the study of specific cancers associated with the post-menopausal state. | STAR Protoc | 2023 |
| 36416812 | Disparities in the Inclusion of Racial and Ethnic Minority Groups and Older Adults in Prostate Cancer Clinical Trials: A Meta-analysis. | JAMA Oncol | 2023 |
| 36862387 | First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer: A Living Systematic Review and Network Meta-analysis. | JAMA Oncol | 2023 |
| 33223367 | Systemic therapy in bladder preservation. | Urol Oncol | 2023 |
| 34294873 | Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancer. | Prostate Cancer Prostatic Dis | 2022 |
| 35652618 | The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases. | Prostate | 2022 |
| 35537621 | Quantifying absolute benefit for adjuvant treatment options in renal cell carcinoma: A living interactive systematic review and network meta-analysis. | Crit Rev Oncol Hematol | 2022 |
| 35690072 | Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021). | Lancet Oncol | 2022 |
| 35483426 | Disparities in Representation of Women, Older Adults, and Racial/Ethnic Minorities in Immune Checkpoint Inhibitor Trials. | Am J Med | 2022 |
| 33824031 | A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma. | Eur Urol | 2021 |
| 33909949 | Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration. | BJU Int | 2021 |
| 33329980 | Evolving Natural History of Metastatic Prostate Cancer. | Cureus | 2020 |
| 31742767 | PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study. | Prostate | 2020 |
| 31353364 | Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma. | Br J Cancer | 2019 |
| 28981385 | Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. | J Clin Oncol | 2018 |
| 29703969 | Role of one, two and three doses of high-dose chemotherapy with autologous transplantation in the treatment of high-risk or relapsed testicular cancer: a systematic review. | Bone Marrow Transplant | 2018 |
| 27158381 | Laminin-binding integrin gene copy number alterations in distinct epithelial-type cancers. | Am J Transl Res | 2016 |
| 27776977 | Emerging role of checkpoint inhibition in localized bladder cancer. | Urol Oncol | 2016 |
| 27678419 | The Cohesive Metastasis Phenotype in Human Prostate Cancer. | Biochim Biophys Acta | 2016 |
| 25160519 | PD-1/PD-L1 in Renal Cell Carcinoma: Projecting the Way Forward. | Clin Genitourin Cancer | 2015 |
| 26366377 | EFFECT OF SELENIUM SUPPLEMENTATION ON PROTEOMIC SERUM BIOMARKERS IN ELDERLY MEN. | J Frailty Aging | 2015 |
| 26235179 | Development of PROSTVAC immunotherapy in prostate cancer. | Future Oncol | 2015 |
| 25648540 | Sequencing systemic therapies for metastatic kidney cancer. | Curr Treat Options Oncol | 2015 |
| 25450035 | Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapy. | Clin Genitourin Cancer | 2015 |
| 23489776 | Selenium supplementation has no effect on serum glucose levels in men at high risk of prostate cancer. | J Diabetes | 2013 |